Nasdaq atai.

Dec 1, 2023 · ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101 ...

Nasdaq atai. Things To Know About Nasdaq atai.

ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock …NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release.Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.. In numbers: Cash, cash ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 ...

ATAI Life Sciences NV Follow Share $1.11 Nov 22, 2:08:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Cybin Inc $0.46 CYBN2.61% Compass Pathways PLC $6.00 CMPS2.92% Mind Medicine...The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.

Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.ATAI Life Sciences News: This is the News-site for the company ATAI Life Sciences on Markets Insider Indices Commodities Currencies Stocks

A high-level overview of Atai Life Sciences N.V. (ATAI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock …The latest price target for ATAI Life Sciences ( NASDAQ: ATAI) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 20.00 expecting ATAI to rise ...-5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...NASDAQ: ATAI LIFE SCIENCES N.V. Instrumentos de la emisora ATAI LIFE SCIENCES N.V. Tipo Valor Serie Isin Estatus Descripción; 1A: N: NL0015000DX5: ACTIVA: ACCIONES SISTEMA INTERNACIONAL DE COTIZACIONES: Estados Financieros. Puede adquirir los reportes financieros trimestrales completos de esta emisora en nuestras .

Aug 8, 2023 · NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...

Company Description. ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive …

Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. ... ATAI Life Sciences NV (NASDAQ:ATAI) 1.07. Delayed Data. As of 3:58pm ET -0.055 ...NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release.Atai Life Sciences N.V. (NASDAQ:ATAI) rose 8.1% to $17.72 in pre-market trading. The company, earlier during the month, reported worse-than-expected Q2 financial results.To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to ...NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

On February 16, Atai Impact, the philanthropic program of Atai Life Sciences (NASDAQ:ATAI) announced it has donated $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS ...Mar 31, 2023 · Shares of Atai Life Sciences ( ATAI 7.69%), a clinical-stage biopharmaceutical company that is developing therapies from psychedelics to treat mental health conditions, saw its shares rise 12.41% ... NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to ...NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.ATAI Life Sciences NV Follow Share $1.11 Nov 22, 2:08:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Cybin Inc $0.46 CYBN2.61% Compass Pathways PLC $6.00 CMPS2.92% Mind Medicine...Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ...A number of companies in the psychedelics space have listed on the Nasdaq this year, including Compass Pathways (NASDAQ:CMPS), MindMed (NASDAQ:MNMD), Atai Life Sciences (NASDAQ:ATAI) and GH ...

Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ...Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares.

I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Apr 28, 2023 · NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, ...Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.

Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ...

With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (ATAI-1.75%) is having a rough go of things lately ...

atai Life Sciences (NASDAQ:ATAI) trades at $1.53, pretty consistent with the prior week’s closing at $1.54. Incannex Healthcare (NASDAQ:IXHL) is trading at $1.4, lower than prior Friday’s ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...Alnylam currently trades on the NASDAQ with a nearly $15 billion market capitalization, justifying Angermayer’s net worth of $700 million. Florian Brand, the co-founder and current CEO of ATAI Life Sciences, comes with a successful entrepreneurial background in the online retail industry.How much insider buying is happening at Atai Life Sciences? Insiders have purchased a total of 1,618,685 ATAI shares in the last 24 months for a total of $3,116,715.96 bought.Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired …Cramer said he likes Enterprise Products Partners L.P. (NYSE:EPD) as it has good dividend, growing volumes and solid management. The "Mad Money" host said Doximity, Inc. (NASDAQ:DOCS) is good, but ...On February 16, Atai Impact, the philanthropic program of Atai Life Sciences (NASDAQ:ATAI) announced it has donated $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS ...8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...Jan 18, 2022 ... In December, it was announced that atai would be added to the Nasdaq's prestigious biotechnology index. ... Atai Life Sciences Has Been Selected ...NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Aug 2, 2023 · As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...

Jun 17, 2022 · Stephen Bardin will join as CFO Designate on June 27, 2022. After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role. NEW YORK and BERLIN ... A number of companies in the psychedelics space have listed on the Nasdaq this year, including Compass Pathways (NASDAQ:CMPS), MindMed (NASDAQ:MNMD), Atai Life Sciences (NASDAQ:ATAI) and GH ...ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.Instagram:https://instagram. c3.ai earningsgreat stocks under 10 dollarsforex trading td ameritradeafter hours crm The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ...Alkermes plc (NASDAQ: ALKS) recently announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company’s novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, taking place March 18-21, 2022. siem market sizeusaa pet Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX. grow tools Atai Life Sciences N.V. (NASDAQ: ATAI) took a significant step to bolster its partnership with IntelGenx Technologies Corp. . The medical technology firm, Atai, now owns a substantial 63% stake in ...The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. ... (NASDAQ: ATAI) reported its financial results and corporate updates for ...Here are our picks for the five psychedelic companies to watch in 2022: Atai Life Sciences, Berlin, Germany – listed on NASDAQ (ATAI) since July, 2021 – Market cap $999 million. Atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is also one of the largest shareholders ...